Thromboelastography (TEG) parameters as potential predictors of malignancy and tumor progression in colorectal cancer.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 101170544 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-7819 (Electronic) Linking ISSN: 14777819 NLM ISO Abbreviation: World J Surg Oncol Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, 2003-
    • Subject Terms:
    • Abstract:
      Purpose: The purpose of this study was to investigate the use of thromboelastography (TEG) in patients with colorectal cancer and to examine whether the TEG parameters can be used as potential markers for disease screening and prediction of disease severity.
      Methods: One-hundred fifteen healthy controls (HC), 43 patients with benign adenoma (BA), and 387 patients with colorectal cancers (CRC) were included in the study. TEG parameters (reaction time, R; clot kinetics, K; alpha angle, α-angle; maximum amplitude, MA), conventional laboratory parameters, and clinical information were collected and analyzed among the HC, BA, and CRC groups. Receiver operating characteristics (ROC) were used for differential analysis. The correlation between TEG parameters and pathological information of CRC (differentiation degree, vaso-nerve infiltration, TNM stage) was analyzed. The differences in TEG parameters at different stages of disease and pre-/post operation were compared.
      Results: Shorter K and higher α-angle/MA were found in patients with CRC compared with HC and BA (P < 0.001). TEG parameters demonstrated moderate diagnostic value (distinguish CRC from HC + BA: K-AUC = 0.693, α-angle-AUC = 0.687, MA-AUC = 0.700) in CRC but did not outperform traditional laboratory parameters. TEG hypercoagulability was closely associated with tumor markers (carcinoma embryonic antigen and carbohydrate antigen 19-9) and pathological information (differentiation degree, vaso-nerve infiltration, and TNM stage) (P < 0.05). Trend analysis showed that K decreased, but α-angle/MA increased gradually as the tumor progressed (P < 0.001). K- and α-angle showed slightly better sensitivity in predicting advanced tumors compared to traditional laboratory parameters. In CRC patients, 3-6 months after tumor resection, K [from 1.8 (1.5, 2.3) to 1.9 (1.6, 2.6)], α-angle [from 65.3 (59.0, 68.6) to 63.7 (56.6, 68.5)], and MA [from 61.0 (58.2, 66.0) to 58.9 (55.8, 61.3)] exhibited modest improvements compared to their preoperative values (P < 0.05).
      Conclusion: TEG parameters possess moderate diagnostic value in CRC diagnosis and predicting advanced tumors, and they are closely linked to surgical interventions. Although TEG parameters do not significantly outperform traditional laboratory parameters, they still hold promise as potential alternative indicators in CRC patients.
      (© 2023. The Author(s).)
    • References:
      Exp Ther Med. 2019 May;17(5):3373-3382. (PMID: 30988714)
      Nat Rev Cancer. 2011 Feb;11(2):123-34. (PMID: 21258396)
      Am J Hematol. 2014 Feb;89(2):228-32. (PMID: 24123050)
      Thromb Res. 2020 Nov;195:55-57. (PMID: 32653602)
      J Clin Lab Anal. 2022 Jan;36(1):e24128. (PMID: 34811805)
      Front Cardiovasc Med. 2022 Oct 13;9:1009926. (PMID: 36312278)
      J Thromb Haemost. 2022 Dec;20(12):2733-2745. (PMID: 36106749)
      Clin Appl Thromb Hemost. 2018 Jul;24(5):755-763. (PMID: 28870084)
      Biomed Res Int. 2021 Oct 19;2021:9623571. (PMID: 34712737)
      Thromb Res. 2015 Jun;135(6):1075-80. (PMID: 25895846)
      Surgery. 2009 Oct;146(4):764-72; discussion 772-4. (PMID: 19789037)
      Cancers (Basel). 2020 Aug 19;12(9):. (PMID: 32825191)
      Am J Surg. 2019 Dec;218(6):1175-1180. (PMID: 31630825)
      Semin Thromb Hemost. 2019 Jun;45(4):413-422. (PMID: 31041799)
      Ann Surg. 2020 Dec;272(6):e288-e289. (PMID: 33055584)
      Cancers (Basel). 2020 Jun 18;12(6):. (PMID: 32570944)
      J Cardiothorac Vasc Anesth. 2023 Jun;37(6):942-947. (PMID: 36933991)
      Cancer Res. 2015 Oct 1;75(19):4235-43. (PMID: 26238780)
      J Clin Lab Anal. 2020 Jan;34(1):e23017. (PMID: 31441128)
      Haematologica. 2020 Jun;105(6):1704-1711. (PMID: 31558668)
      CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. (PMID: 26808342)
      Exp Clin Endocrinol Diabetes. 2020 May;128(5):297-302. (PMID: 30235493)
      Thromb Res. 2010 Apr;125 Suppl 2:S36-8. (PMID: 20434002)
      J Formos Med Assoc. 2022 Jan;121(1 Pt 2):360-366. (PMID: 33994235)
      Ann Surg Oncol. 2010 Jun;17(6):1471-4. (PMID: 20180029)
      Sci Rep. 2020 May 29;10(1):8777. (PMID: 32472080)
      Semin Thromb Hemost. 2019 Jun;45(4):354-372. (PMID: 31108555)
      Dis Markers. 2020 Oct 8;2020:6145604. (PMID: 33133303)
      Med Sci Monit. 2022 May 01;28:e935340. (PMID: 35490293)
      Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820952351. (PMID: 33084538)
      Cancer Manag Res. 2020 Jul 03;12:5373-5384. (PMID: 32753955)
      World J Surg. 2009 Jun;33(6):1298-305. (PMID: 19347392)
      Cell Oncol (Dordr). 2023 Jun;46(3):521-532. (PMID: 36652166)
      J Diabetes Complications. 2022 Aug;36(8):108236. (PMID: 35773172)
      J Am Coll Surg. 2018 Jul;227(1):55-62. (PMID: 29605725)
    • Grant Information:
      ZJB-LK-2023-006 Green Kou Foundation of Zhejiang Blood Transfusion Association; ZJB-LK-2023-006 Green Kou Foundation of Zhejiang Blood Transfusion Association
    • Contributed Indexing:
      Keywords: Colorectal cancer; Conventional laboratory parameters; Diagnosis; Hypercoagulability; Thromboelastography
    • Publication Date:
      Date Created: 20231118 Date Completed: 20231120 Latest Revision: 20231120
    • Publication Date:
      20231120
    • Accession Number:
      PMC10655319
    • Accession Number:
      10.1186/s12957-023-03237-w
    • Accession Number:
      37978382